Anti-N-Methyl-D-Aspartate Receptor Encephalitis
|
0.090 |
Biomarker
|
disease |
BEFREE |
(3) Laboratory examinations: Anti-NMDA receptor IgG in CSF was detected in two patients (2/12, 16.67%), with one patient presented with anti-NMDAR encephalitis associated symptoms.
|
30529926 |
2019 |
Carcinoma
|
0.370 |
Biomarker
|
group |
BEFREE |
(c) Some, but not all, lung carcinomas produced this cytokine, and a close correlation was found between the production of GM-CSF and the number of CD1a+ LC infiltrating these tumors.
|
7679411 |
1993 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
(c) Some, but not all, lung carcinomas produced this cytokine, and a close correlation was found between the production of GM-CSF and the number of CD1a+ LC infiltrating these tumors.
|
7679411 |
1993 |
Cerebrospinal Fluid Rhinorrhea
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
116 cases were identified.The location of leaks was 91 CSF rhinorrhea and 28 CSF otorrhea (3 both).
|
31604132 |
2020 |
Clinically isolated syndrome
|
0.040 |
Biomarker
|
disease |
BEFREE |
34 CIS subjects were enrolled and underwent cerebrospinal fluid oligo-clonal bands (CSF-OCB) evaluation.
|
30953954 |
2019 |
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
3446 individuals (1154 AD cases and 2292 controls) were included in the analyses of AD risk, 1400 individuals (cognitively normal = 747, AD = 653) in the CSF biomarker analyses, and 861 individuals in the analyses of cognitive decline.
|
30792413 |
2019 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
3446 individuals (1154 AD cases and 2292 controls) were included in the analyses of AD risk, 1400 individuals (cognitively normal = 747, AD = 653) in the CSF biomarker analyses, and 861 individuals in the analyses of cognitive decline.
|
30792413 |
2019 |
Hashimoto's encephalitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
375 children were tested for AIE 2011-17 (median age 11.1 years; 54% girls); 18 children (5%) had AIE antibodies (percentage tested positive): CSF GAD<sub>65</sub>-IgG (3.1%), plasma NMDAR-IgG (2.8%), CSF NMDAR-IgG (1.8%), plasma GAD<sub>65</sub>-IgG (1.0%), and plasma CASPR2-IgG (0.4%).
|
31128894 |
2019 |
Frontotemporal Lobar Degeneration
|
0.060 |
Biomarker
|
disease |
BEFREE |
4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.
|
31616982 |
2020 |
GRN-related frontotemporal dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.
|
31616982 |
2020 |
Congenital cerebral hernia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
78 (72.22%) cases had an associated encephalocele with the CSF leak.
|
31604132 |
2020 |
Encephalocele
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
78 (72.22%) cases had an associated encephalocele with the CSF leak.
|
31604132 |
2020 |
Intracranial Hypotension, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
92 patients with SIH were identified and 62 of these patients underwent CSF volume provocation maneuvers.
|
31639606 |
2019 |
Colorectal Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Colorectal cancers are known to be infiltrated by dendritic cells (DC) and neoplastic cells have been shown to produce GM-CSF.
|
10738251 |
2000 |
Advanced Renal Cell Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Advanced renal cell carcinoma treated with granulocyte-macrophage colony-stimulating factor gene therapy: a clinical course of the first Japanese experience.
|
12225344 |
2002 |
Juvenile Myelomonocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo.
|
12384142 |
2002 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.040 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus type 1 infection inhibits granulocyte-macrophage colony-stimulating factor-induced activation of STAT5A in human monocyte-derived macrophages.
|
14610185 |
2003 |
Pulmonary Alveolar Proteinosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Pulmonary alveolar proteinosis (PAP) is an autoimmune disorder characterized by neutralizing autoantibodies to granulocyte-macrophage colony stimulating factor (GM-CSF).
|
16337108 |
2006 |
Pulmonary Alveolar Proteinosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Pulmonary alveolar proteinosis (PAP) is a lung disease characterized by a deficiency of functional granulocyte macrophage colony-stimulating factor (GM-CSF) resulting in surfactant accumulation and lipid-engorged alveolar macrophages.
|
21036914 |
2011 |
Ileitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ileitis was induced in C15KO mice via GM-CSF Ab administration followed by nonsteroidal antiinflammatory drug (NSAID) exposure, and expression of CCL25, CCR9, FOXP3, intracellular cytokines, and RALDH2 was determined in IEC and immune cell populations.
|
21381154 |
2011 |
Nonalcoholic Steatohepatitis
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Nonalcoholic steatohepatitis (NASH), when compared with simple steatosis (SS), significantly increases the expression of TGFB1 (6.8, p<0.005), angiotensin I-converting enzyme (ACE) (2.1, p<0.007), LAMA1 (2.1, p<0.007), SERPINB2 (2.1, p<0.007), CSF2 (2.5, p<0.002), IL1A (2.5, p<0.005), IL3 (2.1, p<0.007), IL4 (2.1, p<0.007), LIF (2.1, p<0.007), and MMP1 (2.1, p<0.007), and decreases the transcript levels of genes involved in the negative regulation of cell-death pathways.
|
21664615 |
2011 |
Juvenile Myelomonocytic Leukemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Juvenile myelomonocytic leukemia is a lethal disease of children characterized by hypersensitivity of hematopoietic progenitors to granulocyte macrophage-colony stimulating factor.
|
22315502 |
2012 |
Juvenile Myelomonocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Juvenile myelomonocytic leukemia is a lethal disease of children characterized by hypersensitivity of hematopoietic progenitors to granulocyte macrophage-colony stimulating factor.
|
22315502 |
2012 |
Juvenile Myelomonocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Juvenile myelomonocytic leukemia (JMML) is characterized by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).
|
23696637 |
2013 |
Juvenile Myelomonocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Juvenile myelomonocytic leukaemia (JMML) is an aggressive myeloproliferative neoplasm in children characterized by granulocyte macrophage colony-stimulating factor (GM-CSF) hypersensitivity and resistance to chemotherapy.
|
24469048 |
2015 |